{"id":104137,"date":"2026-05-26T13:03:07","date_gmt":"2026-05-26T13:03:07","guid":{"rendered":"https:\/\/flamenet.io\/2026\/05\/26\/eu-chmp-issues-positive-opinion-for-perioperative-pembrolizumab-enfortumab-vedotin-in-cisplatin-ineligible-mibc-onclive\/"},"modified":"2026-05-26T13:03:07","modified_gmt":"2026-05-26T13:03:07","slug":"eu-chmp-issues-positive-opinion-for-perioperative-pembrolizumab-enfortumab-vedotin-in-cisplatin-ineligible-mibc-onclive","status":"publish","type":"post","link":"https:\/\/flamenet.io\/2026\/05\/26\/eu-chmp-issues-positive-opinion-for-perioperative-pembrolizumab-enfortumab-vedotin-in-cisplatin-ineligible-mibc-onclive\/","title":{"rendered":"EU CHMP Issues Positive Opinion for Perioperative Pembrolizumab\/Enfortumab Vedotin in Cisplatin-Ineligible MIBC &#8211; OncLive"},"content":{"rendered":"<p><a href=\"https:\/\/news.google.com\/rss\/articles\/CBMi1wFBVV95cUxObkhBSHhucVR6RTBlVS1nclZzYTVLV25rR0F6TUtkTkpicXBVakx0TU00SnMtME51VDU5cnlJMXNqTE9RZ2dMSGkyTUJqVkdMZEtxZUhsSWFHaVF5ZzB3NHFCLUdDWlJxRnpUX3JacGhaZUtqaFY4X0JrbUo5UFFTZUxCNi1RR1hBQU9zY3p0OHZUb0NVMGM2NFllT3h3QTEyU0RxTGdNMENMa0JHckFzcVdIbmFOQlZVX01uby05MloyUDN4aVFKUlpDNm56YU9MT1B3NmFiUQ?oc=5\" target=\"_blank\">EU CHMP Issues Positive Opinion for Perioperative Pembrolizumab\/Enfortumab Vedotin in Cisplatin-Ineligible MIBC<\/a>&nbsp;&nbsp;<font color=\"#6f6f6f\">OncLive<\/font><\/p>\n","protected":false},"excerpt":{"rendered":"<p>EU CHMP Issues Positive Opinion for Perioperative Pembrolizumab\/Enfortumab Vedotin in Cisplatin-Ineligible MIBC&nbsp;&nbsp;OncLive<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[68],"tags":[],"class_list":["post-104137","post","type-post","status-publish","format-standard","hentry","category-opinion"],"_links":{"self":[{"href":"https:\/\/flamenet.io\/api\/wp\/v2\/posts\/104137","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flamenet.io\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flamenet.io\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flamenet.io\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flamenet.io\/api\/wp\/v2\/comments?post=104137"}],"version-history":[{"count":0,"href":"https:\/\/flamenet.io\/api\/wp\/v2\/posts\/104137\/revisions"}],"wp:attachment":[{"href":"https:\/\/flamenet.io\/api\/wp\/v2\/media?parent=104137"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flamenet.io\/api\/wp\/v2\/categories?post=104137"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flamenet.io\/api\/wp\/v2\/tags?post=104137"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}